Schizophrenia’s negative symptoms are the ones that drugs have not solved: the loss of motivation, pleasure, and social drive that often persists after hallucinations and delusions are under control. No FDA-approved drug is specifically indicated to treat them. Since July 30, one product is. It is a smartphone app.

FDA cleared Motivista, developed by Click Therapeutics with Boehringer Ingelheim, as a prescription digital therapeutic “indicated for the treatment of negative symptoms of schizophrenia as an adjunct to clinician-managed outpatient care, including antipsychotic therapy, in patients 18 years of age and older with clinically stable positive symptoms.” Click announced the clearance on October 5 and described Motivista as the first FDA-authorized treatment indicated specifically for those symptoms.

That description holds up against the FDA records searched for this article. What it leaves open is how much the authorization proves. The pivotal trial, published in JAMA Network Open on September 25, showed a small-to-moderate benefit on one clinician-rated scale, in a selected group of stable outpatients, over 16 weeks. A first indication is a regulatory fact. The trial shows how far it sits from a breakthrough.

A category no drug occupies

Antipsychotics are approved to treat schizophrenia, and their clearest effects are on positive symptoms such as hallucinations and delusions. Negative symptoms are a separate domain. The trial’s authors write that drug treatments for the motivation and pleasure deficits have been ineffective and that no earlier Phase 3 study had shown confirmatory efficacy with negative symptoms as its primary endpoint.

The “first” claim can be checked against FDA’s own records. A search of the agency’s drug-label database finds 2,505 labels whose indications mention schizophrenia; none names negative symptoms in its indications section. On the device side, FDA’s product classifications and its clearance, De Novo authorization, and premarket approval records contain no other product named for schizophrenia or psychosis. Among the eight products FDA has authorized under its regulation for computerized behavioral therapy, the others treat substance use, insomnia, depression, and anxiety.

Those searches cover current drug labels and device records by name and classification. They are not a reading of every indication FDA has ever granted, and the claim is bounded by them.

So the precise statement is this: Motivista is the first FDA-authorized treatment specifically indicated for negative symptoms of schizophrenia. It is not the first schizophrenia treatment, and it is not indicated for the disorder as a whole.

What FDA cleared

The authorization is a 510(k) clearance of a Class II device, the pathway for products FDA finds substantially equivalent to one already on the market. It is not a drug approval.

The indication carries four limits. Motivista is adjunctive, used alongside clinician-managed outpatient care and antipsychotic medication, not in place of them. It is for adults. It is for patients whose positive symptoms are clinically stable. And FDA’s summary states that it “has not been studied for treating the positive symptoms of schizophrenia and is not intended for that use.”

The app delivers a 16-week program built from established psychosocial techniques, including behavioral activation, cognitive restructuring, and social skills training, through lessons, goals, and daily check-ins.

What the trial showed

CONVOKE randomized 457 adults at 66 U.S. sites, 227 to Motivista and 230 to a control app, for 16 weeks. All had moderate to severe negative symptoms and stayed on one or two antipsychotics. Raters were centralized and did not know which app a participant had.

The primary measure was the motivation and pleasure subscale of the Clinical Assessment Interview for Negative Symptoms, known as CAINS-MAP, a nine-item clinician-rated scale running from 0 to 36. Participants started at about 26. At week 16, scores fell 6.8 points with Motivista and 4.2 points with the control app, a difference of 2.6 points (95% CI 1.2 to 4.0, p<.001). The standardized effect size, Cohen’s d, was 0.36, with a confidence interval from 0.17 to 0.56. The authors call that small to moderate.

Click’s announcement expresses the same result as a “62% relative improvement.” That figure is the 2.6-point gap divided by the control group’s 4.2-point change. Measured against the scale, the gap is about 7 percent of its range.

Two features of the trial support the primary result. The observed effect of 0.36 was close to the 0.35 the study was powered to detect, which says the trial was sized for the effect it found, not that the effect is large. And the finding held up to missing data: 57 randomized participants had no follow-up assessment, and FDA’s summary says analyses that imputed their scores, including a tipping-point analysis testing how much worse the missing results would have to be, corroborated the primary result.

The control arm matters for reading it. The control app delivered short educational lessons and was designed, the authors write, to be engaging “without therapeutic benefit.” Participants opened it on more days than Motivista, a median of 92 of 112 against 76, but spent a median of two minutes a day in it against six. The control was not an inert placebo, and it was not a treatment. The comparison shows that Motivista outperformed an engaging digital control with no therapeutic content. It does not compare Motivista with clinician-delivered psychosocial therapy, and patients who were in psychotherapy were excluded.

Where the evidence narrows

The benefit shows up on the primary scale and thins out beyond it.

Expressive negative symptoms, such as flattened affect and reduced speech, did not differ between groups (p=.20). Participants’ own global rating of improvement favored Motivista at week 8 and no longer differed significantly at week 16 (p=.07). Positive symptoms did not differ between groups. Within the primary scale, post hoc analyses placed the gain in the social and recreational items; the vocational items showed no difference at week 16. None of the secondary or post hoc analyses was adjusted for multiple comparisons.

The trial’s registration lists six secondary outcomes. The paper reports four. The two it does not report speak to daily life and to the app’s proposed mechanism: social functioning on the Personal and Social Performance Scale, and self-reported defeatist beliefs. FDA’s summary names both among the trial’s secondary endpoints and gives no results for either. The paper’s supplement includes baseline values for “additional secondary end points” and no table of their outcomes, and no results have been posted to the registry. That is an absence from the public record reviewed here. It says nothing about what the results were. It does mean the record does not show whether fewer negative symptoms on a rating scale translated into better functioning.

Nor does the record show how long the effect lasts. In the pivotal trial, assessments stopped when the 16-week program ended, apart from a four-week safety follow-up. Click says an open-label extension study “delivers additional results on engagement and durability of effect.” That study is registered as a single-arm trial of a second 16-week course in 73 participants and was completed in August 2025. No results from it have been posted to the registry, and a PubMed search finds none published. A single-arm study of continued treatment cannot show what happens against a control or after the app is stopped.

The population was narrow by design. Participants were in a stable phase of illness, had been on a stable antipsychotic dose for at least 12 weeks, and needed stable housing, a smartphone, and regular internet access. People with prominent positive symptoms, a moderate or severe substance use disorder, or recent suicidal ideation with a method or intent were excluded. Only four participants were aged 18 to 21, and FDA accepted an extrapolation to cover that group. Participants also saw site staff regularly, which the authors note as a limit on the engagement findings.

The safety record, stated precisely

Click’s announcement says there were no serious treatment-related adverse events. That is accurate, and it is not the whole record.

Serious adverse events occurred in 3 of 228 Motivista participants and 5 of 231 controls, and none was judged related to treatment. One Motivista participant had two events recorded as “psychotic disorder,” which FDA’s summary describes as transient exacerbations of schizophrenia in a 37-year-old man. The first was moderate and resolved two days after an emergency room visit; the second was mild. Both were classified as non-serious and managed with a temporary increase in his risperidone dose, and he stayed on the app. The site investigator and medical monitor rated the events “possibly related” to Motivista. The sponsor rated them “not related.”

On suicidality, FDA’s summary reports that suicidal ideation or behavior was recorded for seven participants in the Motivista arm and four in the control arm after baseline, at 1.1 to 1.5 percent of participants per visit against 0.5 to 0.9 percent. About a quarter of each group had a lifetime history at entry. FDA characterized the incidence as “very low” in both arms, and the trial was not designed to compare the two. The numbers are too small to support a conclusion in either direction. They are a reason to describe the safety profile as favorable in this population, as FDA does, and not as an absence of safety questions.

Why software got there first

Motivista did not need a new regulatory pathway. FDA created a device category for computerized behavioral therapy for psychiatric disorders in 2017, when it authorized the first product of that kind, for substance use disorder. Later products for insomnia, depression, and anxiety were cleared by showing substantial equivalence to an earlier one.

Motivista’s predicate was Rejoyn, the depression app Click developed with Otsuka. FDA’s summary acknowledges that the indication “is not identical” and differs in “the primary psychiatric diagnosis.” The agency found the two substantially equivalent because both are prescription smartphone apps delivering behavioral therapy as an adjunct to standard care, with the difference in indication addressed by the CONVOKE results and by compliance with the special controls that apply to the device class. The product also held Breakthrough Device designation, granted in December 2023 according to the trial’s authors.

The structural point is about which standard applies. A drug for negative symptoms would need FDA approval as a new drug. A behavioral app reached the indication under the device rules, by showing substantial equivalence to an app already cleared and supporting its new use with one pivotal trial against a digital control. That is a different legal test from a drug approval, and it is the one FDA set for this device class nine years ago. A clearance on those terms establishes that the product met it. It does not establish superiority to any other treatment.

Cleared, with launch, price, and coverage undisclosed

In April, Boehringer said it would transfer full responsibility for the product to Click, including commercial and marketing authorization rights, alongside a $50 million investment in Click’s Series D round and unspecified commercial funding. FDA issued the clearance to Click. The public record reviewed here does not show whether the rest of that transfer has been completed, and Click’s October announcement does not mention Boehringer.

That announcement says Motivista is “currently being prepared for broader commercial availability” and that Click is “actively working with payers, providers, and patient advocacy organizations.” It gives no launch date, no price, and no coverage agreement. Medicare has had billing codes for digital mental health treatment devices since 2025, and they apply to devices FDA has cleared and classified under the regulation Motivista falls under. The codes are a billing mechanism, not a coverage decision or a price, and Click has not said how Motivista will be paid for.

Coverage is likely to decide reach. In the trial, 80 percent of participants were unemployed and 64 percent reported income under $25,000. That is an inference from who was enrolled, not a trial finding: for a population like that, whether public insurance programs cover the product matters more than the clearance itself.

What the authorization establishes

Three things are now true. A treatment with a specific FDA indication for negative symptoms exists. A randomized trial showed it reduced clinician-rated motivation and pleasure symptoms more than a control app, by a modest margin. And the evidence that it changes how patients function has not been published, while patients’ own ratings of improvement did not separate significantly from the control at week 16.

The open questions are specific. Neither the functioning results nor the extension study’s results are in the public record reviewed here. Click’s first coverage decision, especially from a Medicaid program, will show whether payers treat a 510(k) clearance as enough. And the authors’ own call for real-world studies in a broader population is the test the pivotal trial could not run: whether people whose illness saps motivation keep using an app when no study site is calling them back.